-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rabson-Mendenhall syndrome (RMS) is the causative mutation caused by the gene of insulin receptor (INSR) are biallelic, insulin resistance leading to diabetes , micro- vascular complications, short stature and growth hormone resistance
Diabetic blood vessels
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
The researchers compared RMS patients treated with metripstin (≥0.
Over time, the A1c of subjects receiving metripstin was 1.
It can be seen that metripstin changed the natural history of elevated A1c in patients with RMS, resulting in a decrease in A1c levels throughout the long-term follow-up
Metripstin changed the natural history of elevated A1c in patients with RMS, resulting in a decrease in A1c levels throughout the long-term follow-up
Original source:
Marinna C Okawa.
Long-term effects of metreleptin in Rabson -Mendenhall Syndrome on glycemia, growth, and kidney function
in this message